According to the company, a booster containing the Corona vaccine from Biontech/Pfizer, which is adapted to the currently predominant Omicron sublines BA.4/BA.5, is significantly more effective than the original vaccine.
New data from an ongoing clinical trial would show an approximately four-fold increase in neutralizing antibodies in the age group over 55 compared to people vaccinated with the original vaccine. Both measurements were reportedly taken a month after the refresher.
Compared with the values for a booster vaccination, a 9.5-fold increase in the so-called antibody titer was found in the group of 18 to 55-year-olds one month after this vaccination. There was a 13.2 fold increase in the over-55s group.
Approved in the EU since September
Both vaccines showed similar safety and tolerability, the companies said. The blood of dozens of people was tested for the study. The BA.4/BA.5 booster from Biontech/Pfizer has been approved in the EU since mid-September. It contains active ingredients against the original Corona variant and against the ommicron sublines BA.4/BA.5.
In early September, 757,000 modified doses of Biontech/Pfizer’s Comirnaty vaccine, which also protects against the omicron variant BA.1, arrived in Austria. Nearly two weeks later, 751,680 doses of the vaccine adapted to the BA.4/BA.5 sublines were delivered. They are already vaccinated in this country.
Source: Krone
I’m Wayne Wickman, a professional journalist and author for Today Times Live. My specialty is covering global news and current events, offering readers a unique perspective on the world’s most pressing issues. I’m passionate about storytelling and helping people stay informed on the goings-on of our planet.
